EMPAVELI
Total Payments
$410,101
Transactions
75
Doctors
21
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $157,006 | 15 | 2 |
| 2023 | $211,117 | 40 | 16 |
| 2022 | $41,979 | 20 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $177,913 | 49 | 43.4% |
| Unspecified | $154,772 | 12 | 37.7% |
| Grant | $66,688 | 1 | 16.3% |
| Space rental or facility fees (teaching hospital only) | $6,500 | 1 | 1.6% |
| Travel and Lodging | $3,995 | 10 | 1.0% |
| Food and Beverage | $234.03 | 2 | 0.1% |
Payments by Type
General
$255,329
63 transactions
Research
$154,772
12 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SOBI-PEGCET-201 | SWEDISH ORPHAN BIOVITRUM AB | $90,468 | 0 |
| SOBI.PEGCET-201 | SWEDISH ORPHAN BIOVITRUM AB | $29,139 | 0 |
| SOBI.PEGCET-119 | SWEDISH ORPHAN BIOVITRUM AB | $24,500 | 0 |
| SOBI.PEGCET-120 | SWEDISH ORPHAN BIOVITRUM AB | $6,110 | 0 |
| SOBI.PEGCET-110 | SWEDISH ORPHAN BIOVITRUM AB | $3,500 | 0 |
| SOBI.PEGCET-101(PEGCETACOPLAN) | SWEDISH ORPHAN BIOVITRUM AB | $1,055 | 0 |
Top Doctors Receiving Payments for EMPAVELI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Orleans, LA | $227,959 | 14 |
| , M.D, | Internal Medicine | Los Angeles, CA | $22,524 | 4 |
| , MD | Medical Oncology | Baltimore, MD | $17,260 | 5 |
| , M.D | Medical Oncology | Indianapolis, IN | $16,445 | 9 |
| , MD | Hematology & Oncology | Tampa, FL | $15,912 | 6 |
| , M.D | Hematology & Oncology | Lawrenceville, GA | $15,814 | 4 |
| , M.D | Hematology | Hackensack, NJ | $12,114 | 6 |
| , M.D | Hematology & Oncology | Salt Lake City, UT | $11,869 | 1 |
| , MD | Hematology & Oncology | Buffalo, NY | $10,610 | 2 |
| , MD | Hematology | Saint Louis, MO | $10,502 | 2 |
| , MD | Medical Oncology | Columbus, OH | $8,105 | 1 |
| , M.D | Hematology & Oncology | Rochester, MN | $6,322 | 3 |
| , MD | Internal Medicine | Los Angeles, CA | $6,227 | 1 |
| , M.D | Hematology | Chicago, IL | $4,834 | 2 |
| , MD | Hematology | Boston, MA | $4,565 | 4 |
| , M.D | Hematology & Oncology | Pembroke Pines, FL | $3,427 | 2 |
| , M.D | Hematology & Oncology | Livingston, NJ | $3,308 | 3 |
| , PA-C | Medical | Kalamazoo, MI | $3,090 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $2,950 | 1 |
| , MD | Medical Oncology | Palo Alto, CA | $2,790 | 2 |
| , PHD | Psychiatry | Evanston, IL | $2,000 | 1 |
| , MD | Hematology & Oncology | Dallas, TX | $1,475 | 1 |
Ad
Manufacturing Companies
- Apellis Pharmaceuticals, Inc. $253,095
- SWEDISH ORPHAN BIOVITRUM AB $154,772
- SOBI, INC $2,234
Product Information
- Type Drug
- Total Payments $410,101
- Total Doctors 21
- Transactions 75
About EMPAVELI
EMPAVELI is a drug associated with $410,101 in payments to 21 healthcare providers, recorded across 75 transactions in the CMS Open Payments database. The primary manufacturer is Apellis Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $157,006 was paid across 15 transactions to 2 doctors.
The most common payment nature for EMPAVELI is "Consulting Fee" ($177,913, 43.4% of total).
EMPAVELI is associated with 6 research studies, including "SOBI-PEGCET-201" ($90,468).